Anti-Human CD52 (Alemtuzumab) [Campath-1H]
Anti-Human CD52 (Alemtuzumab) [Campath-1H]
Product No.: LT200
Product No.LT200 Clone Campath-1H Target CD52 Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names HE5; CDW52; EDDM5 CDW52; Cambridge pathology 1 antigen Isotype Human IgG1κ Applications CyTOF® , ELISA , FA , FC , IHC FF , IHC FFPE , WB |
Antibody DetailsProduct DetailsReactive Species Cynomolgus Monkey ⋅ Rhesus Monkey ⋅ Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen Human lymphocytes. Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% by SDS Page ⋅ ≥95% monomer by analytical SEC Formulation This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Pathogen Testing To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping 2-8°C Wet Ice RRIDAB_2893935 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Alemtuzumab biosimilar antibody for staining cells in flow cytometry is ≤ 0.25 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Applications Reported In Literature ? IHC FFPE (Formalin-fixed paraffin-embedded tissue) IHC FF (Fresh Frozen) FA WB ELISA Additional Reported Applications For Relevant Conjugates ? CyTOF® Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Alemtuzumab. Clone Campath-1H recognizes human CD52. This product is for research use only. Background Clone Campath-1H is a monoclonal antibody that specifically binds to CD52, a protein present on the surface of mature lymphocytes. However, this protein is not present on the stem cells that generated these lymphocytes. Alemtuzumab is targets and destroys mature lymphocytes containing CD-52, and is used to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis. Anti-Human CD52 (Alemtuzumab) utilizes the same variable regions from the therapeutic antibody Alemtuzumab making it ideal for research projects. Antigen Distribution CD52 is primarily expressed on the surface of mature lymphocytes. Additionally, CD52 is present on most lymphoid derived malignancies. However, variable expression on Myeloma cells should be noted. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Research-grade Alemtuzumab biosimilars are used as calibration standards or reference controls in pharmacokinetic (PK) bridging ELISA assays to provide a quantitative basis for measuring drug concentration in serum samples. The calibration standards are essential for generating a reliable standard curve, ensuring the assay’s accuracy and reproducibility for monitoring Alemtuzumab levels. Use of Research-Grade Biosimilars in PK Bridging ELISA
Key Technical Details
In summary: Alemtuzumab biosimilars, when used as calibration standards or reference controls in PK bridging ELISA, provide a validated and reliable quantification basis, ensuring that the assay accurately measures serum drug levels for both innovator and biosimilar forms, which is vital in both clinical monitoring and bioequivalence studies. Research on anti-CD52 antibodies in vivo primarily involves two types of models: syngeneic models and humanized models. Here's a breakdown of how these models are used to study tumor growth inhibition and characterize tumor-infiltrating lymphocytes (TILs): Syngeneic Tumor ModelsSyngeneic models are extensively used in oncology research, including studies on anti-CD52 therapies. These models involve transplanting tumor cells from the same genetic background as the host mice, allowing for the study of tumor-immune interactions within a fully functional immune system.
Humanized Models (e.g., SCID Mice)Humanized models, particularly SCID (Severe Combined Immunodeficiency) mice, are used to study the effects of anti-CD52 antibodies in a more human-relevant context.
To characterize the resulting TILs, researchers typically analyze the immune composition of the tumor microenvironment post-treatment. This involves techniques such as flow cytometry to assess changes in T cell populations, macrophage infiltration, and other immune cell types following the administration of anti-CD52 antibodies. However, specific studies focusing on the characterization of TILs in the context of anti-CD52 therapy are less documented compared to general tumor growth inhibition studies. Typically, TIL characterization involves assessing changes in the immune cell composition within the tumor microenvironment, which can help understand the therapeutic effects of anti-CD52 treatments on tumor immunity. Based on the available research literature, there is currently limited direct evidence of researchers using alemtuzumab biosimilars in combination with other checkpoint inhibitors like anti-CTLA-4 or anti-LAG-3 biosimilars for studying synergistic effects in immune-oncology models. However, the foundational research provides important insights into how such combinations might be approached. Current State of Alemtuzumab Biosimilar ResearchThe development of alemtuzumab biosimilars, such as Mab-TH, has focused primarily on demonstrating equivalence to the original drug through comprehensive preclinical evaluation. Researchers have evaluated these biosimilars using in vitro binding assays, complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) tests, and in vivo models using severe combined immunodeficient (SCID) mice transplanted with human leukemia cell lines. The effective therapeutic dose for both alemtuzumab and its biosimilar Mab-TH has been established at around 10 mg/kg in tumor elimination studies. Checkpoint Inhibitor Combination StrategiesThe rationale for combining multiple checkpoint inhibitors stems from their different mechanisms of action. Anti-CTLA-4 agents primarily function in the lymph node compartment, restoring the induction and proliferation of activated T cells, while anti-PD-1 agents mainly act at the tumor periphery, preventing the neutralization of cytotoxic T cells by PD-L1 expressing tumor cells and plasmacytoid dendritic cells in the tumor microenvironment. Established Combination Approaches Research has demonstrated that targeting multiple checkpoints can increase the activity of each agent and overcome the limitations of monotherapy. The combination of CTLA-4 and PD-1/PD-L1 blockade has shown antitumor efficacy in preclinical models. Clinical trials, such as the CheckMate 067 trial in advanced melanoma, have provided evidence that combination immunotherapy can offer superior outcomes, particularly in PD-L1-negative tumors, where ipilimumab plus nivolumab achieved longer progression-free survival (11.2 months) compared to nivolumab alone (5.3 months). Challenges and Considerations for Future ResearchUnique Mechanism of Alemtuzumab Alemtuzumab's mechanism differs significantly from traditional checkpoint inhibitors. As an anti-CD52 monoclonal antibody, it works by depleting CD52-expressing lymphocytes rather than blocking inhibitory signals. This fundamental difference presents both opportunities and challenges for combination approaches. Limited Preclinical Models A significant constraint in alemtuzumab research is that CD52 is only expressed in old-world primates, limiting the choice of animal models to cynomolgus monkeys for comprehensive safety and toxicology studies. This restriction complicates the development of complex combination studies that would typically rely on more accessible murine models. Safety Profile Considerations The combination of alemtuzumab with other checkpoint inhibitors would likely face significant safety challenges. Alemtuzumab already carries risks of autoimmune thyroid disease, infusion reactions, and increased infection risk, while combination checkpoint inhibitor therapy is known to increase grade 3 or grade 4 toxicities. Potential Research DirectionsFuture research combining alemtuzumab biosimilars with checkpoint inhibitors would likely need to focus on specific clinical contexts where the profound lymphocyte depletion caused by alemtuzumab could be beneficial before immune reconstitution with checkpoint blockade. Such approaches might be particularly relevant in:
The current research landscape suggests that while alemtuzumab biosimilars are being rigorously developed and validated, their integration into complex immune-oncology combination strategies remains largely theoretical and represents an area requiring substantial future investigation. In the context of immunogenicity testing, Alemtuzumab biosimilars can be used as capture or detection reagents in bridging anti-drug antibody (ADA) ELISA assays to monitor a patient's immune response against therapeutic drugs like Alemtuzumab. Here's how it typically works: Bridging ADA ELISA Assay Process
Advantages and Considerations
This method allows researchers to monitor the immune response against Alemtuzumab and its biosimilars, which is important for assessing treatment efficacy and potential side effects associated with ADA formation. References & CitationsTechnical ProtocolsCertificate of Analysis |
Formats Available
Prod No. | Description |
---|---|
LT200 | |
LT203 | |
LT204 | |
LT202 | |
LT201 | |
LT211 | |
LT206 | |
LT205 | |
LT207 |
